Renalytix Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021	2020	2019
Net Income	-45.61	-45.28	-34.73	-9.84	-42.3
Depreciation & Amortization	0.61	0.49	0.28	0.07	0.03
Share-Based Compensation	2.93	4.62	2.66	1.16	0.53
Other Operating Activities	7.98	-5.76	3.38	-0.91	35.59
Operating Cash Flow	-34.09	-45.92	-28.4	-9.52	-6.16
Capital Expenditures	0	-0.66	-1.52	-1.23	-0.31
Acquisitions	0	0	-0.06	0	0
Change in Investments	0	0	0.83	0.06	-0.97
Other Investing Activities	-	-	-	-	-11.02
Investing Cash Flow	0	-0.66	-0.75	-1.17	-12.3
Share Issuance / Repurchase	20.56	9.21	79.55	17.28	29.11
Debt Issued / Paid	-3.18	16.64	0	0.26	-0.44
Other Financing Activities	-0.99	-0.22	-2.31	-1.59	-1.29
Financing Cash Flow	16.39	25.63	77.24	15.94	27.38
Exchange Rate Effect	1.05	-2.84	3.75	-0.15	-0.81
Net Cash Flow	-16.65	-23.8	51.84	5.09	8.12
Free Cash Flow	-34.09	-46.59	-29.92	-10.75	-6.47
Free Cash Flow Margin	-1001.62%	-1568.55%	-2006.77%	-	-
Free Cash Flow Per Share	-0.83	-1.28	-0.84	-0.36	-0.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).